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ABSTRACT
Growth hormone (GH)-releasing hormone and somatostatin modulate
GH secretion. A third mechanism has been discovered in the last
decade, involving the action of GH secretagogues. Ghrelin is a new acy-
lated peptide produced mainly by the stomach, but also synthesized in
the hypothalamus. This compound increases both GH release and food
intake. The relative roles of hypothalamic and circulating ghrelin on GH
secretion are still unknown. Endogenous ghrelin might amplify the basic
pattern of GH secretion, optimizing somatotroph responsiveness to GH-
releasing hormone. This peptide activates multiple interdependent intra-
cellular pathways at the somatotroph, involving protein kinase C, protein
kinase A and extracellular calcium systems. However, as ghrelin induces
a greater release of GH in vivo, its main site of action is the hypothala-
mus. In this paper we review the available data on the discovery of ghre-
lin, the mechanisms of action and possible physiological roles of GH sec-
retagogues and ghrelin on GH secretion, and, finally, the regulation of
GH release in man after intravenous administration of these peptides.
(Arq Bras Endocrinol Metab 2006;50/1:17-24)
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RESUMO
Dos Peptídeos Liberadores do Hormônio de Crescimento (HC) à Ghreli-
na: Descoberta de Novos Moduladores da Secreção de HC
A secreção de hormônio de crescimento (HC) é modulada pelo hor-
mônio liberador de HC e pela somatostatina. Na ultima década foi
descoberto um terceiro mecanismo de controle, envolvendo os secre-
tagogos de HC. A ghrelina é um peptídeo acilado, descoberto recen-
temente, que é produzido no estômago, porém também é sintetizado
no hipotálamo. Este peptídeo é capaz de liberar HC, além de aumentar
a ingestão alimentar. A ghrelina endógena parece amplificar o padrão
básico de secreção de HC, ampliando a resposta do somatotrófo ao
hormônio liberador de HC. Este peptídeo estimula múltiplas vias
intracelulares interdependentes no somatotrófo, envolvendo a proteína
quinase C, proteína quinase A e sistemas moduladores de cálcio
extracelular. Entretanto, como a liberação de HC induzida pela ghrelina
in vivo é mais acentuada que in vitro, seu local de atuação predomi-
nante é no hipotálamo. Nesse artigo  apresentamos uma revisão sobre
a descoberta da ghrelina, os dados existentes sobre os mecanismos de
ação e possível papel fisiológico dos secretagogos de HC e da ghrelina
na secreção de HC e, finalmente, os efeitos da administração
endovenosa destes peptídeos sobre a secreção de HC no homem. (Arq
Bras Endocrinol Metab 2006;50/1:17-24)
Descritores: Ghrelina; GH; Secretagogos de hormônio de crescimento;
GHS
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Historical review
BEFORE THE IDENTIFICATION of the growth hor-mone-releasing hormone (GHRH), Bowers et al.
(1) discovered a group of synthetic compounds with
growth hormone (GH)-releasing properties (for
review see ref. 2). These substances were developed
from the met-enkephalin molecule, through theoreti-
cal calculations, computer modeling, chemical alter-
ations and studies of biological activity. These small
peptides were able to induce a weak GH release ini-
tially. Further chemical changes led to the synthesis of
more potent compounds, including peptides such as
GH releasing peptide-6 (GHRP-6), GHRP-2, hexare-
lin, and non-peptides, as MK-0677, which could be
administered orally (2). In the last decade several stud-
ies were performed with these growth hormone secre-
tagogues (GHS), especially with GHRP-6, and the
obtained data have suggested that these compounds
are modulators of GH release (3). It was shown that
GHS enhance GH secretion by different mechanisms
than those activated by GHRH (for reviews see ref.
2,3), and these substances act through different recep-
tors than those of GHRH, somatostatin or opioid pep-
tides. In 1996 Howard et al. cloned the GHS receptor
(GHS-R), which was mainly found in the anterior
pituitary and in the hypothalamus, and also in other
areas of the central nervous system (4). In 1999 Koji-
ma et al. discovered the endogenous ligand for these
orphan receptors in the stomach, and this new hor-
mone was denominated ghrelin (from ghre, the Indo-
European root of the word grow) (5). Ghrelin is also
present in small amounts in the hypothalamus and is
able to stimulate GH release in a potent manner (5,6).
This peptide is a new member of the brain-gut peptide
family, and it acts in the control of appetite, an effect
that is independent of GH release (for review see ref.
7,8). Ghrelin might have other actions, which are cur-
rently being investigated (7,8). The discovery of ghre-
lin is an example of reverse pharmacology: the chemi-
cal synthesis of compounds, such as GHS, led to the
discovery of the endogenous orphan receptor and,
finally, to the isolation of its natural ligand.
GHS receptor
Howard et al. cloned the GHS receptor in 1996 and
found that it belongs to the G-protein family. The
GHS receptor has seven transmembrane spanning seg-
ments and three intracellular and extracellular loops
(4). Two subtypes of receptors were discovered, GHS-
R1a, which is active, and GHS-R1b, a shorter isoform,
which apparently does not have biological activity (4).
It is likely that other subtypes might exist. The human
GHS-R1a has 366 aminoacids and is highly conserved
in evolution. The active receptor was found in the ante-
rior pituitary and in the hypothalamus, as well as in
other regions of the central nervous system (4). GHS-
R1a is present in several hypothalamic areas, including
the arcuate, ventromedial and paraventricular nuclei
(2,4). GHS-R might modulate biological rhythms,
memory, mood, learning and appetite (2). In the pitu-
itary GHS-R was found exclusively in somatotrophs
(2). In knockout mice for GHS-R1a ghrelin fails to
increase both GH release and food intake, indicating
that both actions of ghrelin are dependent on this type
of receptor. (9). GHS-R1a was also found in other tis-
sues such as pancreas, heart, adrenal gland and the thy-
roid (10). It is interesting that GHS-R1b, the inactive
form, has a widespread distribution in peripheral tissues
but its function has not been elucidated (10).
Ghrelin
In 1999 Kojima et al. surprisingly found a major
increase in intracellular calcium concentrations with
the addition of stomach extracts to an in vitro system
of cells, which expressed GHS-R1a (5). Further stud-
ies led to the isolation of a 28-aminoacid peptide with
a fatty acid chain modification (n-octanoic acid), in the
serine 3 residue. This hydrophobic compound, which
is the first known natural bioactive peptide modified
by an acyl acid, was called ghrelin. It was also found
that ghrelin and the GHS, such as GHRP-6, have no
structural similarity, which is quite intriguing (5). The
post-translational fatty acid chain modification (n-
octanoyl residue) is essential for the biological activity
of ghrelin, including GH release and appetite stimula-
tion. Shorter fragments, with the first four to five
residues, are also able to stimulate signal transduction
of GHS-R1a in vitro when they have an intact acylat-
ed serine (7). However, the main circulating form is
nonacylated ghrelin, which might have non-endocrine
actions (5). Circulating nonacylated ghrelin levels are
reduced by 80% after gastrectomy or gastric bypass in
humans, demonstrating that this peptide is mainly
produced in the stomach (11). It was recently shown
that ghrelin crosses the blood brain barrier, and this
transport occurs in both directions, from the central
nervous system to blood and from blood to brain (12).
It has also been shown that the acyl residue is impor-
tant for this transport (12). The gene that encodes
ghrelin is located on chromosome 3 in men and
encodes a precursor of 117 aminoacids, with an 82%
homology within species (5). Two isoforms of mRNA
of prepro-ghrelin are produced by the same gene, by
alternative splicing, in the stomach (5). One encodes
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the ghrelin precursor while the other encodes des-
Gln14 ghrelin precursor, which has no glutamine on
position 14 (5). This latter peptide has 27 aminoacids
and is biologically active, but is present in small
amounts. Therefore, the main active form is ghrelin.
Ghrelin is found in the submucosal layer of the stom-
ach fundus, in endocrine oxyntic cells (X/A), and also,
in lower concentrations, in the gastrointestinal tract
(7). Both ghrelin and its mRNA are present in the
arcuate nucleus of the hypothalamus and in the pitu-
itary gland (5,10). At pituitary level it might act in
autocrine or paracrine manner. It has been recently
shown that ghrelin is expressed in lactotrophs, soma-
totrophs and thyrotrophs, cells that are dependent, for
differentiation, on Pit 1 gene expression (8). Ghrelin is
also able to modulate Pit-1 transcription. Ghrelin has
a widespread distribution and has been found in the
lung, kidney, ovary, testis, placenta, among others, but
its physiological role in these tissues remains to be elu-
cidated (10). Because the localization of the biological
active receptor (GHS-R1a) is not the same as the pep-
tide, it is likely that other receptor subtypes might exist
(10). Ghrelin is found in considerable amounts in cir-
culation and this peptide has several actions apart from
its modulatory role on GH release (7,8). Ghrelin
enhances food intake, by activation of NPY/AGRP
(agouti-related protein) neurons in the hypothalamus,
while leptin has the opposite effect (7,8). Ghrelin is
able to increase GH release both in animals and in
men, and it also induces PRL, ACTH, cortisol and
aldosterone secretion in vivo (5,6,13,14). Ghrelin
causes a slight increase in glucose levels and a reduc-
tion of circulating insulin (14). The discovery of ghre-
lin reinforced the concept of a third pathway of GH
regulation (2,3,7,8). However, the physiological role
of this potent endogenous GH-releasing peptide
remains to be elucidated.
GHS and Ghrelin: mechanism of action and
possible physiological role on GH release
GHS and ghrelin act both at hypothalamic and pitu-
itary levels to modulate GH secretion (for reviews see
ref. 3,7,8). These peptides stimulate the GHS-R in
pituitary cells in vitro to induce GH release (5). When
GHRH is associated to GHS or ghrelin in vitro, an
additive response is observed in most studies. Howev-
er, when these peptides are administered together with
GHRH in vivo, a synergistic effect on GH release is
observed. This indicates that GHS and GHRH act
through different mechanisms and suggests a main
hypothalamic site of action of GHS (6,14-16). This is
confirmed by the lack of GH release after GHRP-6 or
ghrelin in hypothalamic pituitary disconnection, both
in animals and in men (17,18). It has been shown that
an intact GHRH system is necessary for these actions
to occur. Both GH pulsatility and GH responsiveness
to ghrelin and GHS are decreased by the administra-
tion of antibodies against GHRH in rats (19). GHS-
induced GH release is also blunted by a GHRH antag-
onist (20). GHS are not able to increase GH release in
the lit/lit mouse, which has a GHRH receptor muta-
tion, but they enhance hypothalamic c-fos expression,
which is a marker of neuronal activity (21). GH
response to GHS is inhibited in humans with GHRH
receptor mutations, but the ACTH and PRL releasing
effects are maintained, which suggests that the latter
actions are mediated by the hypothalamus (22). The
arcuate nucleus is the main target of ghrelin action,
where it may bind and activate the GHS-R. GHS and
ghrelin act centrally increasing electrical activity and c-
fos expression in a subpopulation of cells in the arcuate
nucleus, some of which are GHRH producing neu-
rons (21). Moreover, one fourth of these GHRH neu-
rons express the GHS-R, suggesting a direct effect of
GHS in these cells (19). Ghrelin increases GHRH
release from hypothalamic tissue in vitro, but this was
not observed with GHS (23,24). It has also been
shown that GHS increase GHRH release into the pitu-
itary portal system in sheep (25). GHS and ghrelin do
not influence hypothalamic somatostatin release in
most studies, both in vivo and in vitro (23-25). How-
ever, GHS act as functional somatostatin antagonists
(19,26). GHS increase the number of cells secreting
GH and cause depolarization of the somatotroph,
while somatostatin has opposite effects (26). There-
fore, a model of action of GHS/ghrelin has been sug-
gested, which would involve: 1) activation of GHRH
producing neurons in the arcuate nucleus, with an
increase in GHRH release; 2) amplification of the
effect of GHRH at the somatotroph; 3) functional
antagonism of somatostatin (2). GHS/ghrelin and
GHRH bind to different pituitary receptors, and there
is cross-talk between these receptors (for review see
ref. 7). These peptides also stimulate different intracel-
lular transduction pathways at the somatotroph.
GHRH activates intracellular cyclic AMP and protein
kinase A (PKA), while GHRP-6 stimulates protein
kinase C (PKC), via inositol triphosphate signal trans-
duction, with increase in intracellular calcium concen-
trations (figure 1) (2,4). Interestingly, it has been
recently shown that ghrelin activates multiple, interde-
pendent, intracellular pathways in porcine soma-
totrophs, involving PKA, PKC and extracellular calci-
um systems. This effect is broader than the action of
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most GHS, but similar to that described for GHRP-2
in this species (27). These results reinforce the possi-
bility of cross-talk between these transduction path-
ways. However, the physiological role of these potent
GH stimulators is still unclear. Controversial issues are
how the hypothalamic peptide participates in GH
modulation and whether circulating ghrelin has a role
on pituitary GH secretion. In the rat ghrelin secretion
occurs in a pulsatile manner, but has no correlation
with GH pulses and is associated to food and sleep
cycles (28). Circulating ghrelin levels are similar dur-
ing GH peak and trough periods in the rat (29). Ghre-
lin immunoneutralization does not interfere with GH
pulsatility, while GHRH antibodies block endogenous
pulsatile GH release (30). In humans GHRH antago-
nist administration strongly inhibits 24h GH secre-
tion, but fails to affect circulating ghrelin levels (31).
However, in rats, intracerebroventricular or peripheral
administration of GHSR-1A antagonists attenuates
spontaneous GH secretion, due to a decrease in pulse
amplitude and mean GH levels (32-34). Interestingly,
a missense mutation in the GHS receptor, which
severely impaired ghrelin binding, was associated with
a case of familial short stature (35). It has also been
shown in healthy volunteers that circulating ghrelin is
related to GH pulses, suggesting that ghrelin partici-
pates in the pulsatile regulation of GH secretion or
that the two hormones are regulated in parallel (36).
Therefore, endogenous ghrelin might amplify the
basic pattern of GH secretion (32-34). This peptide
may also have a physiological role in GH release by
optimizing somatotroph responsiveness to GHRH
(37). Nevertheless, recent studies with ghrelin knock-
out animals failed to show a major effect on GH reg-
ulation (38). In contrast to predictions, these animals
were not anorexic dwarfs (38). However, in transgenic
models with decreased GHS-R mRNA expression in
the arcuate nucleus, reduced GH and IGF-I levels
were observed (39). Also, GHS-R knockout mouse
had lower body weight and IGF-I values (40). These
effects were only moderate, which is intriguing, as
these peptides are quite potent GH stimulators. It has
been previously suggested that the role of ghrelin on
GH secretion might become more relevant during
states of negative energy balance (30). However, fur-
ther studies will be necessary to elucidate the physio-
logical role of these peptides on GH secretion.
Modulation of GH release by GHRP-6 and
Ghrelin in man
GHRP-6 and ghrelin increase GH release in a dose
dependent manner, both in vivo and in vitro in several
species, including man (1,5,6,13,16). The GH relea-
sing activity of ghrelin is similar to that of GHRH in
vitro (5). However, iv ghrelin administration at a dose
of 1 µg/kg increases GH release potently in man, and
this response is higher than that obtained with
GHRH, hexarelin and GHRP-6 (13,14,41). This
effect is not specific as an increase in PRL, ACTH, cor-
tisol and aldosterone levels is also observed (14). Glu-
cose levels increase and insulin values decrease after iv
administration of this peptide (14). These latter effects
and the aldosterone stimulation are not seen with
other GHS. When ghrelin or GHRP-6 are adminis-
tered together with GHRH a synergistic effect is seen,
but this is better observed with injections of ghrelin at
low doses (0,08 and 0,2 µg/kg) (14,16). The admin-
istration of GHRP-6 together with GHRH is an excel-
lent test to diagnose GH deficiency in adults, but its
usefulness in children is less clear (42). There is a high-
ly reproducible response for GHS in normal subjects,
studied in different occasions, differently than that
observed for GHRH. There are no gender differences
in the GH response to GHRP-6 and ghrelin
(3,15,43), but an age related decrease of responsive-
ness has been reported for both peptides (3,15,43). It
has been shown that obese subjects have blunted GH
responses to GHRP-6 and ghrelin (44,45). Ghrelin-
induced GH release is decreased by 55% in women
with visceral adiposity and BMI of 362 kg/m2 (45).
Hyperglycemia, free fatty acids and somatostatin
decrease GHRP-6 and ghrelin-induced GH response
(46,47). Arginine was not able to alter GH respon-
siveness to ghrelin (48). The effect of cholinergic ago-
Figure 1. Schematic model of the possible interactions
between GHRH, ghrelin/GHS and SRIF at hypothalamic and
pituitary level.
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nists and antagonists on ghrelin-induced GH release is
controversial. Piridostigmine failed to modify GH
responsiveness to both ghrelin and GHRP-6 (15,48).
However, atropine blunted this response, but piren-
zepine, a muscarinic receptor antagonist, was unable
to alter GH release after ghrelin (49). These latter
compounds only blunt GH response to GHRP-6,
while they completely abolish GH response to GHRH
(15). GH response to GHS was only attenuated by
glucocorticoids and GH administration, which proba-
bly enhance hypothalamic somatostatin release
(50,51). In patients with Cushing’s disease a blunted
GH response to both GHRP-6 and ghrelin has been
reported by us and by others (52-55). In these patients
GHS and ghrelin-induced ACTH and cortisol release
is increased (54,55). These latter effects could be due
to a direct action of these peptides at GHS-R in the
corticotroph adenoma or, alternatively, activation of
hypothalamic AVP and probably, to a lesser extent, of
CRH pathways (7). Interestingly, chronic glucocorti-
coid administration does not interfere with GHRP-6
induced GH release (53). It has been previously sug-
gested that the time of exposure to hypercortisolism is
important for the GH response to these peptides. In
patients with adrenal insufficiency a 72 h withdrawal of
glucocorticoid replacement therapy does not influence
the GH responsiveness to GHRP-6 (57). We have
shown that in hyperthyroidism there is a decrease in
GH responsiveness to GHRH while GHRP-6-induced
GH release is maintained, which could suggest that
thyroid hormones interfere mainly with GHRH-
releasing mechanisms (58). However, we have recent-
ly shown that there is a decrease in the GH response
to ghrelin in these patients, suggesting that thyroid
hormones might interfere with additional pathways of
GH release activated by ghrelin (figure 2) (59). In
type 1 diabetes mellitus GH response to GHRP-6 and
hexarelin is either normal or enhanced, demonstrating
that hyperglycemia is unable to decrease GH release
induced by these peptides, differently than in normal
subjects (60). It has recently been shown that ghrelin-
induced GH release is decreased in anorexia nervosa,
which is an unexpected finding as these patients have
high GH levels and enhanced responses to GHRH
and GHS (61). GH-releasing compounds could repre-
sent an alternative treatment in GH deficient states.
However, these substances have failed to show benefit
over GH therapy, despite the fact that they are more
physiological, as they induce endogenous pulsatile GH
release.
CONCLUSION
Ghrelin is a novel hormone secreted from the stomach
to the circulation. This peptide is also produced in the
hypothalamus and other tissues, with both endocrine
and paracrine effects. The acyl modification of its mol-
ecule is essential for enhancement of GH release and
stimulation of food intake. Several questions remain to
be answered concerning the roles of circulating and
hypothalamic ghrelin on GH release. Ghrelin might
have a physiological role on pulsatile GH secretion,
but further studies are necessary to clarify its precise
role on GH modulation.
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